Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis

American Journal of Pathology

Volumn 175, Issue 1, 2009, Pages 430-439

  Hosaka, Tomoko ^a   Kimura, Hiroshi ^a   Heishi, Takahiro ^a   Suzuki, Yasuhiro ^a   Miyashita, Hiroki ^a   Ohta, Hideki ^b   Sonoda, Hikaru ^b   Moriya, Takuya ^c,d   Suzuki, Satoshi ^a   Kondo, Takashi ^a   Sato, Yasufumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOHIBIN 1;

ADD ON THERAPY; ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; TUMOR VASCULARIZATION; VASOHIBIN 1 GENE;

EID: 67649969173     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080788     Document Type: Article

References (35)

1. Yano S, Matsumori Y, Ikuta K, Ogino H, Doljinsuren T, Sone S: Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 2006, 11:73-81
2. Jain RK: Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer. Nat Rev Cancer 2008, 8:309-316
3. Stinchcombe TE, Socinski MA: Bevacizumab in the treatment of nonsmall-cell lung cancer. Oncogene 2007, 26:3691-3698
4. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005, 438:967-974
5. Bremnes RM, Camps C, Sirera R: Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006, 51:143-158
6. Mattern J, Koomagi R, Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996, 73:931-934
7. Takanami I, Imamura T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, Kodaira S: Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma. Jpn J Clin Oncol 1996, 26:293-297
8. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 2005, 3:4-10
9. Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007, 26:281-290
10. Swinson DE, O"Byrne KJ: Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clin Lung Cancer 2006, 7:250-256
11. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66:1095-1104
12. Sato Y: Update on endogenous inhibitors of angiogenesis. Endothelium 2006, 13:147-155
13. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584
14. Fontanini G, Boldrini L, Calcinai A, Chine S, Lucchi M, Mussi A, Angeletti CA, Basolo F, Bevilacqua G: Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res 1999, 5:155-161
15. Yamaguchi M, Sugio K, Ondo K, Yano T, Sugimachi K: Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 2002, 36:143-150
16. Mascaux C, Martin B, Paesmans M, Verdebout JM, Verhest A, Vermylen P, Bosschaerts T, Ninane V, Sculier JP: Expression of thrombospondin in non-small cell lung cancer. Anticancer Res 2002, 22:1273-1277
17. Dudek AZ, Mahaseth H: Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005, 23:193-200
18. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, Sonoda H, Sato Y: Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004, 114:898-907
19. Shibuya T, Watanabe K, Yamashita H, Shimizu K, Miyashita H, Abe M, Moriya T, Ohta H, Sonoda H, Shimosegawa T, Tabayashi K, Sato Y: Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler Thromb Vasc Biol 2006, 26:1051-1057
20. Shimizu K, Watanabe K, Yamashita H, Abe M, Yoshimatsu H, Ohta H, Sonoda H, Sato Y: Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem Biophys Res Commun 2005, 327:700-706
21. Koizumi T, Abe M, Yamakuni T, Ohizumi Y, Hitotsuyanagi Y, Takeya K, Sato Y: Metronomic scheduling of a cyclic hexapeptide Ra-VII for anti-angiogenesis, tumor vessel maturation and anti-tumor activity. Cancer Sci 2006, 97:665-674
22. Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K, Sonoda H, Ohta H, Fujiwara T, Shimosegawa T, Sato Y: Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood 2009, 113:4810-4818
23. Yamashita H, Abe M, Watanabe K, Shimizu K, Moriya T, Sato A, Satomi S, Ohta H, Sonoda H, Sato Y: Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem Biophys Res Commun 2006, 345:919-925
24. Li G, Tian L, Hou JM, Ding ZY, He QM, Feng P, Wen YJ, Xiao F, Yao B, Zhang R, Peng F, Jiang Y, Luo F, Zhao X, Zhang L, Zhou Q, Wei YQ: Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 2005, 11:4217-4224
25. Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF: The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res 2007, 13:2191-2198
26. Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E, Kelley MJ: Expression of HIF-1α. CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005, 49:325-335
27. McDonald DM, Foss AJ: Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 2000, 19:109-120
28. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 1998, 18:2701-2710
29. Petrovic N, Bhagwat SV, Ratzan WJ, Ostrowski MC, Shapiro LH: CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells. J Biol Chem 2003, 278:49358-49368
30. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW: Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202
31. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW: Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006, 108:2339-2348
32. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B: Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11:539-554
33. Yoshinaga K, Ito K, Moriya T, Nagase S, Takano T, Niikura H, Yaegashi N, Sato Y: Expression of vasohibin as a novel endotheliumderived angiogenesis inhibitor in endometrial cancer. Cancer Sci 2008, 99:914-919
34. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364
35. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62